Based on all these negative findings, the National Comprehensive Cancer Network (NCCN) clinical practice guidelines of NSCLC (version 4, 2021) did not recommend immunotherapy for treating EGFR-mutant NSCLCs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.